Tasly (Hong Kong) Pharmaceutical Investment Limited - Net Worth and Insider Trading

Tasly (Hong Kong) Pharmaceutical Investment Limited Net Worth

The estimated net worth of Tasly (Hong Kong) Pharmaceutical Investment Limited is at least $775 Million dollars as of 2025-06-11. Tasly (Hong Kong) Pharmaceutical Investment Limited is the 2501 Other of Immunotech Biopharm Ltd and owns about 243,075,721 shares of Immunotech Biopharm Ltd (HKSE:06978) stock worth over $775 Million. Details can be seen in Tasly (Hong Kong) Pharmaceutical Investment Limited's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Tasly (Hong Kong) Pharmaceutical Investment Limited has not made any transactions after 2024-12-30 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Tasly (Hong Kong) Pharmaceutical Investment Limited

Tasly (Hong Kong) Pharmaceutical Investment Limited Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Tasly (Hong Kong) Pharmaceutical Investment Limited owns 1 companies in total, including Immunotech Biopharm Ltd (HKSE:06978) .

Click here to see the complete history of Tasly (Hong Kong) Pharmaceutical Investment Limited’s form 4 insider trades.

Insider Ownership Summary of Tasly (Hong Kong) Pharmaceutical Investment Limited

Ticker	Company	Transaction Date	Type of Owner
HKSE:06978	Immunotech Biopharm Ltd	2025-01-03	2501 Other

Tasly (Hong Kong) Pharmaceutical Investment Limited Latest Holdings Summary

Tasly (Hong Kong) Pharmaceutical Investment Limited currently owns a total of 1 stock. Tasly (Hong Kong) Pharmaceutical Investment Limited owns 243,075,721 shares of Immunotech Biopharm Ltd (HKSE:06978) as of December 30, 2024, with a value of $775 Million.

Latest Holdings of Tasly (Hong Kong) Pharmaceutical Investment Limited

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
HKSE:06978	Immunotech Biopharm Ltd	2024-12-30	243,075,721	3.19	775,411,550

Holding Weightings of Tasly (Hong Kong) Pharmaceutical Investment Limited

Tasly (Hong Kong) Pharmaceutical Investment Limited Form 4 Trading Tracker

According to the SEC Form 4 filings, Tasly (Hong Kong) Pharmaceutical Investment Limited has made a total of 4 transactions in Immunotech Biopharm Ltd (HKSE:06978) over the past 5 years, including 0 buys and 0 sells. The most-recent trade in Immunotech Biopharm Ltd is the sale of 0 shares on December 30, 2024, which brought Tasly (Hong Kong) Pharmaceutical Investment Limited around $0.

Insider Trading History of Tasly (Hong Kong) Pharmaceutical Investment Limited

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Tasly (Hong Kong) Pharmaceutical Investment Limited Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Tasly (Hong Kong) Pharmaceutical Investment Limited Ownership Network

Ownership Network List of Tasly (Hong Kong) Pharmaceutical Investment Limited

No Data

Ownership Network Relation of Tasly (Hong Kong) Pharmaceutical Investment Limited

Tasly (Hong Kong) Pharmaceutical Investment Limited Owned Company Details

What does Immunotech Biopharm Ltd do?

Who are the key executives at Immunotech Biopharm Ltd?

Tasly (Hong Kong) Pharmaceutical Investment Limited is the 2501 Other of Immunotech Biopharm Ltd. Other key executives at Immunotech Biopharm Ltd include Jung Hyun Chul , Evodevo LTD , and 2501 Other Yan Kaijing .

Immunotech Biopharm Ltd (HKSE:06978) Insider Trades Summary

Over the past 18 months, Tasly (Hong Kong) Pharmaceutical Investment Limited made 1 insider transaction in Immunotech Biopharm Ltd (HKSE:06978) with a net sale of 0. Other recent insider transactions involving Immunotech Biopharm Ltd (HKSE:06978) include a net sale of 0 shares made by Jung Hyun Chul , a net sale of 0 shares made by Evodevo Ltd , and a net sale of 0 shares made by Yan Xijun .

In summary, during the past 3 months, insiders sold 0 shares of Immunotech Biopharm Ltd (HKSE:06978) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Immunotech Biopharm Ltd (HKSE:06978) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Immunotech Biopharm Ltd (HKSE:06978)'s detailed insider trading history can be found in Insider Trading Tracker table.

Immunotech Biopharm Ltd Insider Transactions

No Available Data

Tasly (Hong Kong) Pharmaceutical Investment Limited Mailing Address

Above is the net worth, insider trading, and ownership report for Tasly (Hong Kong) Pharmaceutical Investment Limited. Currently GuruFocus does not have mailing address information for Tasly (Hong Kong) Pharmaceutical Investment Limited.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.